Key result
A commercial bivalent FMD vaccine combined with epidemiological strategies was useful to control field strains when used in periodic biannual vaccination campaigns.
Why the study?
Does a commercial bivalent FMD vaccine protect against the 2010 field virus from Ecuador?
Does a commercial bivalent FMD vaccine protect against the 2010 field virus from Ecuador?
A commercial bivalent FMD vaccine containing older strains (O1 Campos Br/58 and A24 Cruzeiro Br/55) is effective in controlling the 2010 field virus in Ecuador when used in biannual campaigns.
Supports strategic vaccine deployment for FMD control; leaves open prospective field validation of long-term impact.
Foot-and-Mouth Disease serotype O circulated endemically in Ecuador for many years, with an upsurge occurring in 2009. This manuscript describes retrospectively in vitro and in vivo laboratory studies to predict the field effectiveness of a commercial FMD vaccine to protect against the field strain, and explains the key actions and epidemiological strategies followed by the country to control the disease. The results established that the use of a good quality oil vaccine, manufactured with strains that were isolated long ago: O1 Campos Br/58 and A24 Cruzeiro Br/55; combined with the correct epidemiological strategies, are useful to control field strains when used in periodic biannual vaccination campaigns.
No takes yet. Share an insight, caveat, or question.
Duque et al. (2016) studied Foot-and-Mouth Disease. Commercial bivalent FMD vaccine (O1 Campos Br/58 and A24 Cruzeiro Br/55) was evaluated on Field effectiveness to protect against the field strain. A commercial bivalent FMD vaccine combined with epidemiological strategies was useful to control field strains when used in periodic biannual vaccination campaigns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: